Vetencourt R, Oropeza F, de Armas J, Cordero I, de Silva M, Machado I, Vetencourt M, Mendoza J
Servicio de Gastroenterología, Hospital Central Antonio María Pineda, Barquisimeto, Caracas.
G E N. 1990 Oct-Dec;44(4):353-60.
Twenty children with chronic Hepatitis B virus infection where treated with alfa interferon 2b and compared with a group of 24 non treated patients with similar age and sex distribution. Both treated and untreated patients, all Hepatitis B surface antigen positive for a minimum of 6 months, were divided in 2 groups according to HBeAg status: positive and negative. The treatment was ambulatory at a dose of 5.000.000 U per square meter of body surface, administered 3 times a week during 16 weeks. Tolerance of the drug was good with secondary reactions only at the beginning of the treatment. The only change in laboratory tests was the normalization of aminotransferases in HBeAg positive children. There was no significant difference between the treated and untreated group of HBeAg positive patients regarding the rate of HBeAg seroconversion. There was a striking difference in negativization of HBsAg in HBeAg negative patients: 8% in the treated group and 81% in the untreated group, this is explained by important epidemiological differences between both groups.
20名慢性乙型肝炎病毒感染儿童接受了α干扰素2b治疗,并与一组年龄和性别分布相似的24名未治疗患者进行了比较。所有接受治疗和未接受治疗的患者,乙肝表面抗原均呈阳性至少6个月,根据HBeAg状态分为两组:阳性和阴性。治疗为门诊治疗,剂量为每平方米体表面积500万单位,每周给药3次,持续16周。药物耐受性良好,仅在治疗开始时出现次要反应。实验室检查的唯一变化是HBeAg阳性儿童的转氨酶恢复正常。在HBeAg阳性患者的治疗组和未治疗组之间,HBeAg血清学转换率没有显著差异。HBeAg阴性患者的HBsAg转阴率存在显著差异:治疗组为8%,未治疗组为81%,这是由两组之间重要的流行病学差异所解释的。